Bitcoin 854.35
$58,893.00 1.45068%
Ethereum 146.81
$4,123.01 3.5608%
XRP 0.09
$1.59 5.51224%
Zcash 11.80
$311.60 3.78765%
Monero 22.39
$483.18 4.6341%
Tether 0.00
$1.00 0.16901%
Elite 0.00
$0.00 -2.10646%
Developing a suite of Class Leading Immunotherapeutics
Token sale completed on 22 February
Goal: Not set
Website Whitepaper

Xeophin has devised a funding pathway to develop the XeRA-1 Therapeutic for Rheumatoid Arthritis, however this offering represents much more than stake in a promising pharmaceutical. Xeophins’ unique approach to Biotech funding can change the paradigm of how medicine is financed. Xeophin is tokenizing 50% of the future royalties generated by XeRA-1, allowing its’ token holders to fund, and benefit from its’ success. Our mission is to take our core technologies and drive them through our six step process. The outcome being a transaction-ready and IP protected technology portfolio, tokenized. From then on, Xeophin will undertake commercialization activities to achieve a significant royalty deal, delivering value to our XeRA-1 Token holders. Being backed by a physical asset, the XeRA-1 Arthritis Therapeutic, the XERA1 token can increase in value as milestones are hit on the road to commercialization. Once live, token holders will yield cash royalty payments, commensurate to XeRA-1s’ earnings.

Token Sale: 20 August — 22 February
ICO Token Price
Min/Max Personal Cap

Add a comment

Member of The Internet Defense League